Skip to main content
Fig. 1 | BMC Veterinary Research

Fig. 1

From: Anti-tumor effects of rivoceranib against canine melanoma and mammary gland tumour in vitro and in vivo mouse xenograft models

Fig. 1

Effects of rivoceranib on the proliferation of canine solid tumour cell lines in vitro. A, B Viability of LMeC and CHMp cells after treatment with different concentrations of rivoceranib at 24, 48, and 72 h of treatment. All experiments were performed in triplicate. The data represent the mean ± standard deviation obtained from three independent experiments. * p < 0.05, ** p < 0.01 versus the control group (0.5% dimethyl sulfoxide) at the same time point

Back to article page

BMC Veterinary Research

ISSN: 1746-6148

Contact us